UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 136

Sortiert nach

The SOFA score-development, utility and challenges of accurate assessment in clinical trials

Critical care (London, England), 2019-11, Vol.23 (1), p.374-374, Article 374

2019

Volltextzugriff (PDF)

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Critical care (London, England), 2017-08, Vol.21 (1), p.213-213, Article 213

2017

Volltextzugriff (PDF)

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

The New England journal of medicine, 2001-03, Vol.344 (10), p.699-709

2001

Volltextzugriff (PDF)

Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome

The New England journal of medicine, 2004-08, Vol.351 (9), p.884-892

2004

Volltextzugriff (PDF)

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study

ERJ open research, 2023-01, Vol.9 (1), p.342

2023

Volltextzugriff (PDF)

The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients

Critical care (London, England), 2020-06, Vol.24 (1), p.289-289, Article 289

2020

Volltextzugriff (PDF)

Myeloid-related protein-8/14 facilitates bacterial growth during pneumococcal pneumonia

Thorax, 2014-11, Vol.69 (11), p.1034-1042

2014

Volltextzugriff (PDF)

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Critical care (London, England), 2020-07, Vol.24 (1), p.410-410, Article 410

2020

Volltextzugriff (PDF)

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Critical care (London, England), 2004-04, Vol.8 (2), p.R82-R90

2004

Volltextzugriff (PDF)

Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome

American journal of respiratory and critical care medicine, 2021-11, Vol.204 (9), p.1024-1034

2021

Volltextzugriff (PDF)

Convalescent Plasma for Covid-19-Induced ARDS. Reply

The New England journal of medicine, 2024-01, Vol.390 (4), p.386-386

2024

Volltextzugriff (PDF)

Aerosol delivery during invasive mechanical ventilation: a systematic review

Critical care (London, England), 2017-10, Vol.21 (1), p.264-264, Article 264

2017

Volltextzugriff (PDF)

Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

Critical care (London, England), 2018-01, Vol.22 (1), p.8-8, Article 8

2018

Volltextzugriff (PDF)

Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

PloS one, 2016-05, Vol.11 (5), p.e0156299-e0156299

2016

Volltextzugriff (PDF)

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

Critical care (London, England), 2008-01, Vol.12 Suppl 6 (Suppl 6), p.S4-S4

Laterre, Pierre-Francois

2008

Volltextzugriff (PDF)

Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

The New England journal of medicine, 2023-10, Vol.389 (17), p.1590-1600

2023

Volltextzugriff (PDF)

sTREM-1 is a specific biomarker of TREM-1 pathway activation

Cellular & molecular immunology, 2021-08, Vol.18 (8), p.2054-2056

2021

Volltextzugriff (PDF)

Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19

Scientific reports, 2022-06, Vol.12 (1), p.9959-9959, Article 9959

2022

Volltextzugriff (PDF)

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-01, Vol.14 (4), p.R126-R126

2010

Volltextzugriff (PDF)

Breakthrough in cardiac arrest: reports from the 4th Paris International Conference

Annals of Intensive Care, 2015-09, Vol.5 (1), p.22-22, Article 22

2015

Volltextzugriff (PDF)

Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study

Shock (Augusta, Ga.), 2018-04, Vol.49 (4), p.385-392

2018

Volltextzugriff (PDF)

Serum uric acid, disease severity and outcomes in COVID-19

Critical care (London, England), 2021-06, Vol.25 (1), p.1-212, Article 212

2021

Volltextzugriff (PDF)

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

BMJ open, 2019-02, Vol.9 (2), p.e024475

2019

Volltextzugriff (PDF)

Selepressin for Patients With Septic Shock-Reply

JAMA : the journal of the American Medical Association, 2020-02, Vol.323 (7), p.667

2020

Volltextzugriff (PDF)

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

Critical care (London, England), 2008-01, Vol.12 Suppl 6 (Suppl 6), p.S1-S1

Laterre, Pierre-Francois

2008

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR Complete Journals

ThemaAged

KollektionEZB Electronic Journals Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(134)

Publikationsform

Artikel
(130)
Berichte
(5)
Webseiten
(1)

Sprache

Englisch
(134)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The SOFA score-development, utility and challenges of accurate assessment in clinical trials

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study

The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients

Myeloid-related protein-8/14 facilitates bacterial growth during pneumococcal pneumonia

Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome

Convalescent Plasma for Covid-19-Induced ARDS. Reply

Aerosol delivery during invasive mechanical ventilation: a systematic review

Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition

Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients

sTREM-1 is a specific biomarker of TREM-1 pathway activation

Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

Breakthrough in cardiac arrest: reports from the 4th Paris International Conference

Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study

Serum uric acid, disease severity and outcomes in COVID-19

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Selepressin for Patients With Septic Shock-Reply

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

Aktive Filter

Suchergebnisse filtern